Epsilogen, the global leader in the development of immunoglobulin E (IgE) antibody therapeutics, announces that it has completed the acquisition of TigaTx, Inc., a biotechnology company developing engineered immunoglobulin A (IgA) antibodies, to create the world’s leading pan-isotype cancer antibody company. The acquisition not only gives Epsilogen the capability of selecting the appropriate antibody isotype for a given cancer, given the differentiated therapeutic mechanisms of each, but also allows it to mix and match IgE, IgA and IgG functionality into a single antibody molecule.
Read the full article: Epsilogen Announces Acquisition of TigaTx, Inc. to Create World’s Leading Pan-Isotype Cancer Antibody Company //
Source: https://www.businesswire.com/news/home/20250406268542/en/Epsilogen-Announces-Acquisition-of-TigaTx-Inc.-to-Create-Worlds-Leading-Pan-Isotype-Cancer-Antibody-Company